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Rationale: Bronchodilator responsiveness (BDR) is a common but variable phenomenon in COPD. The CT
characteristics of airway dimensions that differentiate COPD subjects with BDR from those without BDR have not
been well described. We aimed to assess airway dimensions in COPD subjects with and without BDR.
Methods: We analyzed subjects with GOLD 1–4 disease in the COPDGene® study who had CT airway analysis. We
divided patients into two groups: BDR + (post bronchodilator ΔFEV1≥ 10%) and BDR-(post bronchodilator ΔFEV1 < 10%).
The mean wall area percent (WA%) of six segmental bronchi in each subject was quantified using VIDA. Using 3D
SLICER, airway wall thickness was also expressed as the square root wall area of an airway of 10 mm (Pi10) and 15 mm
(Pi15) diameter. %Emphysema and %gas trapping were also calculated.
Results: 2355 subjects in the BDR-group and 1306 in the BDR + group formed our analysis. The BDR + group had a
greater Pi10, Pi15, and mean segmental WA% compared to the BDR-group. In multivariate logistic regression using
gender, race, current smoking, history of asthma, %emphysema, %gas trapping, %predicted FEV1, and %predicted FVC,
airway wall measures remained independent predictors of BDR. Using a threshold change in FEV1≥ 15% and FEV1≥
12% and 200 mL to divide patients into groups, the results were similar.
Conclusion: BDR in COPD is independently associated with CT evidence of airway pathology. This study provides us
with greater evidence of changes in lung structure that correlate with physiologic manifestations of airflow obstruction
in COPD.
Keywords: Bronchodilator responsiveness, Airway wall thickness, Chronic obstructive pulmonary disease, Airflow
obstructionIntroduction
COPD is classically associated with irreversible or poorly
reversible airflow obstruction [1], which helps to distin-
guish it from asthma. However, the concept that asthma
and COPD have a similar pathogenesis was initially de-
scribed by Orie et al. in 1961 [2]. This concept, known
as the “Dutch Hypothesis,” sparked tremendous debate,
with many researchers arguing that COPD and asthma
are distinct entities [3,4]. Nevertheless, bronchodilator
responsiveness (BDR) is present in 54-83% of COPD pa-
tients [5-7]. To complicate matters, this phenomenon in
COPD is not a consistent one; BDR is present on some* Correspondence: victor.kim@tuhs.temple.edu
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unless otherwise stated.occasions but not others during serial lung function test-
ing of the same subject [7,8]. BDR may have significant
clinical importance in COPD; some studies showed that
BDR is associated with a faster rate of lung function de-
cline [9,10], mortality [11,12], and the development of
airflow obstruction [13], whereas others have not [14].
It is currently unclear why some patients with COPD
demonstrate BDR. A crucial pathologic feature of COPD
is airway inflammation, which results in epithelial remod-
eling, smooth muscle hypertrophy, subepithelial fibrosis,
and mucous cell metaplasia [15]. Several investigators
have correlated airway remodeling and degree of airflow
obstruction in COPD [16-18]. Similarly, airway wall thick-
ness on CT scan correlates with degree of airflow obstruc-
tion in several studies [19-21]. However, CT correlates of
BDR in COPD have not been well described.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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asthma airway pathology is dominated by smooth
muscle hypertrophy, it is reasonable to hypothesize that
COPD patients with BDR have a greater degree of air-
way smooth muscle mass, and therefore thicker airways
on CT imaging. We analyzed the 3661 subjects with
COPD with quantified airway measurements in the Gen-
etic Epidemiology of COPD Study (COPDGene®). We
hypothesized that patients with BDR would have greater
CT measures of airway pathology and less emphysema
compared to those without BDR.
Methods
The Genetic Epidemiology of COPD (COPDGene®) Study
is a multicenter observational study to analyze genetic sus-
ceptibility for the development of COPD. This study was
IRB approved at all institutions (Temple IRB #11369). In-
clusion and exclusion criteria were described previously
[22]. Briefly, enrollees are African-American or non-
Hispanic Caucasian between the ages of 45 and 80 with at
least a 10 pack-year smoking history. Exclusion criteria in-
clude pregnancy, history of other lung diseases except
asthma, prior lobectomy or lung volume reduction, active
cancer undergoing treatment, known or suspected lung
cancer.
Lung function testing and group assignment
We included patients with GOLD 1 through 4 disease se-
verity in our analysis as defined by an FEV1/FVC ratio <
70. Each subject underwent pre- and post-bronchodilator
spirometry using an EasyOne™ spirometer (Zurich,
Switzerland) before and after the administration of 2
puffs of albuterol with spacer device. Bronchodilators
were held prior to spirometry in usual fashion. Predicted
values were obtained using NHANES III data [23]. BDR
was assessed as an FEV1 % change after bronchodilator
[(FEV1postBD – FEV1preBD)/FEV1preBD] × 100. 10% was
used as a threshold of BDR. The patients were divided into
two groups: BDR+, defined as ≥10% change in FEV1 [BDR+
(10%)], and BDR-, defined as <10% change in FEV1 [BDR-
(10%)]. Thresholds of ≥15% change and ≥12% and 200 mL
in FEV1(American Thoracic Society criteria for BDR) were
also analyzed separately as dividing points between groups
[BDR + (15%) and BDR-(15%), BDR + (ATS) and BDR-
(ATS)].
Computed tomography
Volumetric CT acquisitions were obtained at full inspir-
ation and at the end of normal expiration. Thin-slice
collimation with slice thickness and intervals of < lmm
was used to enhance spatial resolution. Quantitative
image analysis to calculate lung volumes, percent em-
physema, and percent gas-trapping was performed using
3D SLICER (http://www.slicer.org/). Percent emphysemawas defined as the total percentage of both lungs with at-
tenuation values < −950 Hounsfield units on inspiratory
images, and percent gas trapping was defined as the total
percentage of both lungs with attenuation values < −856
Hounsfield units on expiratory images. Total lung capacity
and functional residual capacity were calculated based on
inspiratory and expiratory CT images, respectively. Airway
disease was quantified using VIDA Diagnostics Inc.’s PW
workstation software (http://www.vidadiagnostics.com)
as wall area percent (WA%: (wall area/total bronchial
area)×100) [9]. The mean WA% was calculated as the
average of six segmental bronchi in each subject. Using
3D SLICER, airway wall thickness was also expressed as
the square root wall area of a 10 mm diameter airway
(Pi10) and 15 mm diameter airway (Pi15) as previously de-
scribed [21].
Statistical analysis
Analysis was performed using SPSS v21.0. Categorical
variables were compared between groups using Chi
squared test. Continuous variables were evaluated using
2-tailed unpaired t test. Wilcoxon rank sum test was
used for non-normally distributed data. A p value <0.05
was considered statistically significant. Pearson correla-
tions were performed between the measures of airway
wall thickness and percent change in FEV1. Multivariate
logistic regressions were performed to assess the inde-
pendent effects of airway dimensions on BDR, using the
10%, 15%, and ATS dividing points in separate models
with current smoking, history of asthma, %emphysema,
%gas trapping, FEV1 %predicted, and FVC %predicted as
covariates. FEV1/FVC ratio was excluded due to signifi-
cant co-linearity with spirometric parameters. In
addition, a multivariate linear regression was performed
for SGRQ scores, mMRC dyspnea scores, total and se-
vere exacerbations as outcomes of interest with lung
function and BDR as covariates.
Results
There were 1306 subjects in the BDR + (10%) group
(35.7% of total) and 2355 subjects in the BDR-(10%)
group. Baseline subject characteristics are summarized
in Table 1. The BDR + (10%) group was older, was less
likely to be currently smoking, had a greater history of
asthma, worse lung function, higher BODE indices,
worse health related quality of life (SGRQ scores),
greater dyspnea, and greater total and severe exacerba-
tion frequency compared to the BDR-(10%) group. There
were no differences in gender, race, BMI, or 6-min walk
distance. Similarly, the BDR + (15%) (n = 798, 21.8% of
total) group had a greater smoking history, history of
asthma, higher BODE indices, worse SGRQ scores,
greater dyspnea, worse lung function, and greater total
exacerbation history compared to the BDR-(15%) group
Table 1 Baseline characteristics
BDR-(10%) BDR + (10%) BDR-(15%) BDR + (15%) BDR-(ATS) BDR + (ATS)
n = 2355 n = 1306 p n = 2863 n = 798 p n = 2385 n = 1276 p
Age at enrollment 62.94 ± 8.43 63.55 ± 8.78 .039 63.04 ± 8.49 63.58 ± 8.83 .111 63.16 ± 8.36 63.15 ± 8.93 .963
Gender (% male) 57.4 55.1 .191 57.1 54.5 .185 56.8 56.1 .700
Race (% Caucasian) 79.1 79.9 .569 79.4 79.2 .905 79.6 78.9 .638
BMI (kg/m2) 27.71 ± 5.90 28.05 ± 6.03 .094 27.74 ± 5.93 28.16 ± 6.00 .073 27.71 ± 5.95 28.06 ± 5.95 .090
Smoking History (pack yrs) 51.72 ± 27.08 52.35 ± 27.18 .502 51.38 ± 26.74 53.98 ± 28.32 .017 52.05 ± 27.07 51.75 ± 27.03 .748
Current Smoking (%) 45.0 39.5 .001 43.8 40.4 .082 43.6 42.1 .401
Distance walked, ft 1262.57 ± 410.64 1237.53 ± 394.89 .077 1266.14 ± 409.31 1208.67 ± 387.07 <.0001 1253.44 ± 413.03 1254.04 ± 390.33 .966
History of Asthma (%) 21.3 27.6 <.0001 21.9 29.6 <.0001 22.2 26.2 .017
BODE index 2.25 ± 2.12 2.72 ± 2.05 <.0001 2.28 ± 2.10 2.94 ± 2.03 <.0001 2.35 ± 2.13 2.55 ± 2.05 .007
SGRQ score 34.49 ± 22.77 39.07 ± 22.47 <.0001 34.79 ± 22.87 40.91 ± 21.73 <.0001 35.22 ± 22.78 37.80 ± 22.65 .001
mMRC dyspnea score 1.80 ± 1.47 1.99 ± 1.43 <.0001 1.80 ± 1.47 2.11 ± 1.39 <.0001 1.82 ± 1.46 1.94 ± 1.45 .022
FEV1% pred 60.25 ± 23.51 53.90 ± 20.74 <.0001 59.82 ± 23.23 51.4 ± 19.63 <.0001 58.95 ± 23.24 56.17 ± 21.73 <.0001
FVC% pred 83.45 ± 20.52 80.88 ± 19.59 <.0001 83.37 ± 20.50 79.52 ± 18.91 <.0001 81.87 ± 20.35 83.77 ± 19.94 .007
FEV1/FVC 0.54 ± 0.13 0.50 ± 0.13 <.0001 0.53 ± 0.13 0.49 ± 0.13 <.0001 0.53 ± 0.13 0.50 ± 0.13 <.0001
FEV1% change 1.74 ± 6.46 20.10 ± 10.82 <.0001 3.60 ± 7.13 25.10 ± 11.22 <.0001 2.86 ± 7.50 18.43 ± 12.48 <.0001
FVC% change 2.94 ± 9.21 17.85 ± 20.58 <.0001 4.40 ± 9.85 22.13 ± 24.15 <.0001 1.43 ± 7.13 21.02 ± 19.78 <.0001
Exacerbation Frequency 0.59 ± 1.12 0.71 ± 1.22 .002 0.61 ± 1.14 0.70 ± 1.22 .047 0.61 ± 1.14 0.67 ± 1.19 .146
Severe Exacerbations 17.5 20.7 .018 18.1 20.4 .140 18.3 19.3 .476
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BDR + (10%) and BDR-(10%) groups, the BDR + (15%)
group had a lower 6-minute walk distance, and did not
have a greater history of severe exacerbations (defined as
an exacerbation requiring an emergency room visit or
hospitalization) compared to the BDR-(15%) group.
Similar to the BDR + (10%) and BDR + (15%) groups, the
BDR + (ATS) group (n = 1276, 34.9% total) had worse
lung function, higher SGRQ scores, BODE scores, and
mMRC dyspnea scores, but there were no differences in
total and severe exacerbations. In all groups, percent
change in FVC was greater in the BDR + groups.
When a multivariate linear regression was performed
for SGRQ scores, mMRC dyspnea scores, total and se-
vere exacerbations as outcomes of interest with FEV1 %
predicted, FVC %predicted, and BDR by either 10%,
15%, or ATS criteria as covariates, BDR was not a sig-
nificant predictor for these outcomes. This indicates that
the differences in dyspnea, health related quality of life,
and exacerbations were more likely a consequence of the
differences in lung function in the BDR + groups.
Quantitative CT measurements are summarized in
Table 2. The BDR + (10%) group had slightly more %em-
physema, had more %gas trapping, and a higher func-
tional residual capacity compared to the BDR-(10%)
group. Total lung capacity was not different between
groups. Pi10, Pi15, and WA% were significantly greater
in the BDR + (10%) group compared to the BDR-(10%)
group. The results were similar with the BDR + (15%)
and BDR-(15%) groups, but the differences was slightly
greater compared to the differences between the BDR +
(10%) and BDR-(10%) groups. The BDR + (ATS) group
had greater Pi10, Pi15, and WA% compared to the BDR-
(ATS) group. In contrast to the other two groups, the
BDR + (ATS) group had similar %emphysema and a
lower FRC compared to the BDR-(ATS) group.Table 2 Quantitative CT measurements
BDR-(10%) BDR + (10%) BDR-(15%)
n = 2355 n = 1306 p n = 2863
%emphysema 11.36 ± 12.34 12.22 ± 11.96 .042 11.43 ± 12.23
%gas trapping 33.96 ± 20.93 39.04 ± 20.22 <.0001 34.46 ± 20.85
TLC 6.01 ± 1.43 6.09 ± 1.47 .090 6.01 ± 1.44
FRC 3.78 ± 1.2 4.05 ± 1.24 <.0001 3.80 ± 1.20
TLC %pred,
race-adjusted
101.15 ± 16.52 103.65 ± 16.42 <.0001 101.34 ± 16.49
FRC %pred,
race-adjusted
117.90 ± 31.85 127.02 ± 31.12 <.0001 118.62 ± 31.69
Pi10 3.69 ± 0.14 3.73 ± 0.15 <.0001 3.69 ± 0.14
Pi15 5.17 ± 0.2 5.24 ± 0.21 <.0001 5.18 ± 0.20
Wall area %,
segmental
61.97 ± 3.15 63.12 ± 2.94 <.0001 62.08 ± 3.12
Definition of Abbreviations: TLC total lung capacity, FRC functional residual capacity.Table 3 summarizes airway dimensions according to
BDR + (10%) or BDR-(10%) by GOLD stage. In each
GOLD stage, Pi10, Pi15, and WA% is greater in the
BDR + (10%) group, with the exception of Pi10 in GOLD
3 subjects. This is depicted in Figure 1. The three vari-
ables for airway thickness were weakly related to percent
change in FEV1 as a continuous variable. The correlation
coefficients for Pi10, Pi15, and WA% are 0.148, 0.145,
and 0.167, respectively, p < 0.0001 for all relationships.
Figure 2 demonstrates the relationship between WA%
and BDR.
Table 4 summarizes the odds ratios and 95% confi-
dence intervals for the multivariate logistic regressions
for the three measures of bronchodilator responsiveness
(BDR ≥ 10%, BDR ≥ 15%, BDR + by ATS criteria) as the
outcomes of interest with using the three measures of
airway wall thickness as predictors of interest in separate
models. All three measures of airway wall measures had
significant odds ratios for bronchodilator responsiveness.
The most significant odds ratios were for Pi15 (4.60
[95% CI 3.13, 6.75], 5.35 [95% CI 3.48, 8.24], and 5.13
[95% CI 3.46, 7.61] for BDR + (10%), (15%), and (ATS),
respectively). Asthma history was not a significant pre-
dictor of BDR in these multivariate models (1.07 [95% CI
0.99, 1.15], 0.99 [95% CI 0.91, 1.08], and 0.97 [95% CI 0.81,
1.16] for BDR + (10%), (15%), and (ATS), respectively).
Discussion
We have demonstrated that subjects with BDR have CT
evidence of thicker airways than non BDR subjects using
three different thresholds for change in FEV1. We also
showed that the two groups divided by changes in FEV1
were similar in terms of race and gender distribution,
but had higher BODE indices, worse lung function,
worse health related quality of life and dyspnea, and
greater exacerbation frequency. To our knowledge, thisBDR + (15%) BDR-(ATS) BDR + (ATS)
n = 798 p n = 2385 n = 1276 p
12.53 ± 12.12 .024 11.78 ± 12.77 11.45 ± 11.96 .431
40.48 ± 20.00 <.0001 34.93 ± 20.88 37.36 ± 20.61 .001
6.11 ± 1.48 .095 5.96 ± 1.44 6.31 ± 1.44 .134
4.15 ± 1.25 <.0001 3.87 ± 1.25 3.89 ± 1.10 <.0001
104.56 ± 16.44 <.0001 101.56 ± 16.41 102.94 ± 16.70 .016
130.25 ± 30.95 <.0001 118.86 ± 31.55 125.43 ± 32.10 <.0001
3.74 ± 0.15 <.0001 3.69 ± 0.14 3.72 ± 0.15 <.0001
5.26 ± 0.21 <.0001 5.17 ± 0.20 5.24 ± 0.21 <.0001
63.45 ± 2.89 <.0001 62.07 ± 3.14 62.97 ± 3.00 <.0001
Table 3 Airway dimensions by GOLD stage
GOLD Variable BDR-(10%) BDR + (10%) p
1 n = 519 n = 143
Pi10 3.62 ± 0.10 3.64 ± 0.12 .016
Pi15 5.08 ± 0.15 5.14 ± 0.19 <.0001
WA%, Seg 60.04 ± 2.66 61.32 ± 2.99 <.0001
2 n = 1029 n = 564
Pi10 3.68 ± 0.12 3.71 ± 0.15 <.0001
Pi15 5.19 ± 0.21 5.23 ± 0.21 <.0001
WA%, Seg 62.06 ± 3.01 62.90 ± 2.90 <.0001
3 n = 501 n = 425
Pi10 3.74 ± 0.14 3.75 ± 0.15 .289
Pi15 5.22 ± 0.22 5.27 ± 0.21 .001
WA%, Seg 63.04 ± 3.02 63.64 ± 2.81 .002
4 n = 506 n = 174
Pi10 3.75 ± 0.14 3.78 ± 0.13 .031
Pi15 5.19 ± 0.20 5.24 ± 0.21 .004
WA%, Seg 63.20 ± 3.01 64.02 ± 2.60 .003
Figure 1 Airway dimensions in those that are BDR + (10%) and
BDR-(10%) according to GOLD stage. Data presented as mean ±
SD. A) Pi10, B) Pi15, and C) WA%. *p < 0.05. †p < 0.0001.
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of subjects with and without BDR.
We chose FEV1 to determine BDR using several cutoff
values based on prior studies [24,25] because of the no-
tion that changes in FEV1 may be more reflective of air-
way disease. In addition to percent changes, we also
analyzed an absolute change in FEV1 to divide subjects
into groups. Indeed, many patients with COPD, particu-
larly those with worse disease, demonstrate responsive-
ness to bronchodilator by an increase in FVC as
opposed to FEV1 [26]. This may represent decreases in
air trapping and dynamic airway collapse during forced
expiratory maneuvers [27]. In our study, we found that
those with BDR by FEV1 criteria also had significantly
greater increases in FVC, and thus could also be labeled
“volume responders” in addition to “flow responders” [14].
Studies have shown conflicting results in clinical out-
comes of BDR in COPD. There are some studies that
show an accelerated decline in lung function in revers-
ible patients, whereas other studies have not [9,14,28]. In
the Evaluation of COPD Longitudinally to Identify Pre-
dictive Surrogate Endpoints (ECLIPSE), a three year pro-
spective observational study, patients with BDR had a
17 ± 4 ml per year greater rate of decline in FEV1 com-
pared to those without BDR [9], but no differences in
mortality, hospitalizations, or exacerbations were found
[29]. Bronchial hyper-responsiveness was found to accel-
erate lung function decline in over 7,000 individuals and
conferred an odds ratio of 4.5 for the development of
COPD [13]. However, Nishimura et al. categorized
GOLD 1–4 COPD patients into rapid decliners, slow de-
cliners, and sustainers of lung function and found nodifference in the presence of BDR among these three
groups [14]. Similarly, there was no relationship between
BDR and rate of lung function decline in the Inhaled
Steroids in Obstructive Lung Disease in Europe trial
(ISOLDE) or the Understanding Potential Long-term Im-
provements in Function with Tiotropium trial (UPLIFT)
[24,28]. In addition, acute bronchodilator responsiveness
did not predict improvements in lung function with tio-
tropium [24]. Therefore, it is unclear if BDR in COPD has
any clinical significance.
Part of the problem lies in the variability in the defin-
ition of BDR across studies and the inconsistency of
BDR in COPD subjects over time. Calverley et al. found
that 52% of 660 patients with serial lung function testing
switched responder status to bronchodilator [8]. In the
Figure 2 Relationship between WA% and percent change in FEV1.
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65% of patients had at least 1 visit with 15% improvement
in lung function with administration of isoproterenol over
a period of 2 years [30]. Another complicating matter is
that using American Thoracic Society criteria of a change
in FEV1 of 12% and 200 cc may be too restrictive for sub-
jects with very severe airflow obstruction [31]. For some-
one with an FEV1 of 800 cc, for example, a change of
200 cc would translate into a change of 25%, a change
much greater than 12%. In addition, many patients with
severe COPD demonstrate a change in FVC acutely, not
necessarily FEV1, in response to bronchodilator [26].
Thus, a practical, consistent definition of BDR is needed
in order to understand the importance of this physiologic
phenomenon.
Regardless of its clinical consequences, BDR is associ-
ated with thicker airways based on quantitative CT im-
aging. The reason for these observed differences is not
clear, but our results are hypothesis generating. It is pos-
sible that genetic influences have bearing on BDR inTable 4 Multivariate logistic regression for bronchodilator rev
BDR + (10%) BDR
OR 95% CI OR
Pi10 4.59 2.62 8.06 6.27
Pi15 4.60 3.13 6.75 5.35
WA% Segmental 1.11 1.08 1.14 1.12
Using each variable in lefthand column in a separate model with gender, race, curr
FVC %pred as covariates. P < 0.001 for all odds ratios.COPD, accounting for both the physiologic and CT dif-
ferences between those with and without BDR. Indeed,
one study revealed greater BDR in smokers of first de-
gree relatives with early onset COPD [32], and another
identified several genomic regions that could contain
loci regulating BDR [33]. If that is the case, then this
could mean there are different potential therapeutic tar-
gets for those with BDR. This would have to be con-
firmed with more extensive genetic analysis. In addition,
we have shown that advanced emphysema patients with
greater airway smooth muscle mass were more likely to
demonstrate BDR on lung function testing [34]. Other
investigators have found direct correlations with the de-
gree of smooth muscle mass and airflow obstruction in
COPD [16,17]. The increased CT airway thickness in the
BDR groups may represent a greater degree of smooth
muscle hypertrophy, which is thought to be the patho-
logic correlate in asthma responsible for bronchodilator
responsiveness and airway hyper-responsiveness. These
findings, however, must be confirmed in studies that alsoersibility
+ (15%) BDR + (ATS)
95% CI OR 95% CI
3.33 11.79 5.82 3.30 10.24
3.48 8.24 5.13 3.46 7.61
1.09 1.16 1.10 1.07 1.13
ent smoking, history of asthma, %emphysema, %gas trapping, FEV1 %pred, and
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confirm our results pathologically. Finally, it has been
proposed that gas trapping may be a surrogate marker
for airway disease in COPD; the association between
BDR and gas trapping in our cohort is consistent with
this notion.
Of interest was the finding that percent emphysema
and percent gas trapping were greater in those in the
BDR + (10%) and BDR + (15%) groups, but there was no
difference in emphysema in the BDR + (ATS) group.
This most likely reflects the differences in lung function
between the groups; FEV1 and FVC %predicted were
lower in the BDR + (10%) and BDR + (15%) groups and
higher in the BDR + (ATS) group. This phenomenon likely
is a result of greater ease in achieving an absolute change
of 200 mL with bronchodilator in those with better lung
function. In addition, in the multivariate models for BDR +
presented in Table 4, %emphysema had slightly but signifi-
cantly reduced odds ratios for BDR, and %gas trapping had
slightly but significantly greater odds ratios for BDR. This is
consistent with prior studies that have found lower percent
emphysema is associated with BDR [35].
This study has some noteworthy limitations. Firstly,
lung function testing was only performed once, leading
to the possibility of inconsistency and lack of repeatability
of the response to bronchodilator during serial testing.
Some subjects that were not reversible may demonstrate
reversibility on their next measure of airflow by spirom-
etry [8]. Secondly, outcomes such as exacerbation and
asthma history were by subject self-report, lending to re-
call bias. In addition, the inclusion of subjects with
asthma, whether or not the diagnosis was made by a phys-
ician, is a limitation of the study. Thirdly, the differences
in airway measurements were small between groups, mak-
ing the significance of the data questionable. However, the
multivariate analyses clearly show BDR, using various def-
initions, to increase the odds of having thicker airways. Fi-
nally, many of the clinical phenotypic differences are most
likely the result of differences in lung function between
the two groups.
Conclusions
We show that quantitative CT measures of airway thick-
ness are greater in those with bronchodilator responsive-
ness. This is one more step towards bridging the gap
between radiological and pathological correlations. How
these differences in airway thickness translates to airway
pathology remains to be determined.
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